Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 16/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 16/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6908297 | 0.76 | CYP11B1 (0.48) | CYP11B2CYP11B1CYP19A1KMT2ATDP1 | |
| SCHEMBL22526144 | 0.73 | CYP11B2 (0.55) | CYP11B2CYP11B1CYP19A1CYP17A1KMT2A | |
| SCHEMBL1884215 | 0.71 | CYP11B1 (0.76) | CYP11B2CYP11B1CYP19A1CYP17A1 | |
| SCHEMBL1883378 | 0.69 | CYP11B1 (0.63) | CYP11B2CYP11B1CYP19A1CYP17A1 | |
| SCHEMBL17281110 | 0.67 | KMT2A (0.50) | CYP11B2CYP11B1CYP19A1KMT2ATDP1 | |
| SCHEMBL6907650 | 0.67 | CYP11B1 (0.62) | CYP11B2CYP11B1CYP19A1CYP17A1KMT2A | |
| SCHEMBL15850901 | 0.65 | CYP11B1 (0.64) | CYP11B2CYP11B1 | |
| SCHEMBL1762396 | 0.65 | CYP11B2 (1.00) | CYP11B2CYP11B1CYP19A1 | |
| SCHEMBL1881056 | 0.62 | CYP11B2 (0.60) | CYP11B2CYP11B1 | |
| SCHEMBL22385036 | 0.62 | KDM4E (0.35) | CYP11B2CYP11B1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541404-B2 | Inhibitors of the human aldosterone synthase CYP11B2 | ELEXOPHARM GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20110118241-A1 | 6-Pyridin-3-YL-3,4-Dihydro-1H-Quinolin-2-One Derivatives and Related Compounds as Inhibitors of the Human Aldosterone Synthase CYP11B2 | UNIVERSITAT DES SAARLANDES (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110112067-A1 | Inhibitors of the Human Aldosterone Sythase CYP11B2 | UNIVERSITAT DES SAARLANDES (DE) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118241-A1 | 6-Pyridin-3-YL-3,4-Dihydro-1H-Quinolin-2-One Derivatives and Related Compounds as Inhibitors of the Human Aldosterone Synthase CYP11B2 | HSD11B1, HSD11B2, CYP4A11 | CYP11B2 4/4885CYP11B1 6/4885CYP19A1 52/4885 |
| US-20110112067-A1 | Inhibitors of the Human Aldosterone Sythase CYP11B2 | HSD11B1, HSD11B2, CYP11B1 | CYP11B2 4/4885CYP11B1 3/4885CYP19A1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.